LU135252, an endothelin(A) receptor antagonist did not prevent pulmonary vascular remodelling or lung fibrosis in a rat model of myocardial infarction

British Journal of Pharmacology

Volumn 130, Issue 7, 2000, Pages 1525-1530

  Nguyen, Quang Trinh ^a   Colombo, Federico ^a   Rouleau, Jean L ^b   Dupuis, Jocelyn ^a   Calderone, Angelino ^a  

^a MONTREAL HEART INSTITUTE   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Coronary ligation; Endothelin 1; ET(A) receptor; Extracellular matrix proteins; Pulmonary hypertension; Pulmonary vascular remodelling; Transforming growth factor

Indexed keywords

COLLAGEN; DARUSENTAN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST; FIBRONECTIN; MESSENGER RNA; SCLEROPROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY WALL; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY LIGATION; DISEASE COURSE; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; LUNG BLOOD VESSEL; LUNG FIBROSIS; MALE; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAT; SYSTOLIC BLOOD PRESSURE;

EID: 0033868175     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0703466     Document Type: Article

References (33)

1. BARTON, M., D'USCIO, L.V., SHAW, S., MEYER, P., MOREAU, P. & LUSCHER, T.F. (1998). ET(A) receptor blockade prevents increased tissue endothelin-1, vascular hypertrophy, and endothelial dysfunction in salt-sensitive hypertension. Hypertension, 31(1 pt 2), 499-504.
2. BATTISTINI, B. & DUSSAULT, P. (1998). Blocking of the endothelin system: The development of receptor antagonists. Pulmon. Pharmacol. Therapeut., 11, 97-112.
3. CALDERONE, A., TAKAHASHI, N., THAIK, C. & COLUCCI, W.S. (1998). A trial natriuretic peptide, nitric oxide and cGMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts. J. Clin. Invest., 101, 812-818.
4. CODY, R.J., HAAS, G.J., BINKLEY, P.F., CAPERS, Q. & KELLEY, R. (1992). Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation, 85, 504-509.
5. COKER, R.K., LAURENT, G.J., SHAHZEIDI, S., LYMPANY, P.A., DU BOIS, R.M., JEFFERY, P.K. & MCANULTY, R.J. (1997). Transforming growth factors-beta 1, -beta 2, and -beta 3 stimulate fibroblast procollagen production in vitro but are differentially expressed during bleomycin-induced lung fibrosis. Am. J. Pathol., 150, 981-991.
6. A-receptor antagonist prevents and reverses chronic hypoxia-induced pulmonary hypertension in rat. Am. J. Physiol., 269, L690-L697.
7. EICKELBERG, O., KOHLER, E., REICHENBERGER, F., BERTSCHIN, S., WOODTLI, T., ERNE, P., PERRUCHOUD, A.P. & ROTH, M. (1999). Extracellular matrix deposition by primary human lung fibroblasts in response to TGF-beta1 and TGF-beta3. Am. J. Physiol., 216, L814-824.
8. GUARDA, E., KATWA, L.C., MYERS, P.R., TYAGI, S.C. & WEBER, K.T. (1993). Effects of endothelins on collagen turnover in cardiac fibroblasts. Cardiovasc. Res., 21, 2130-2134.
9. GUTIERREZ, S., PALACIOS, I., EGIDO, J., GOMEZ-GARRE, D., HERNANDEZ, P., GONZALEZ, E. & HERRERO-BEAUMONT, G. (1996). Endothelin-1 induces loss of proteoglycans and enhances fibronectin and collagen production in cultured rabbit synovial cells. Eur. J. Pharmacol., 302, 191-197.
10. HAFIZI, S., ALLEN, S.P., GOODWIN, A.T., CHESTER, A.H. & YACOUB, M.H. (1999). Endothelin-1 stimulates proliferation of human coronary smooth muscle cells via the ET(A) receptor and is co-mitogenic with growth factors. Atherosclerosis, 146, 351-359.
11. HAY, D.W. (1999). Putative mediator role of endothelin-1 in asthma and other lung diseases. Clin. Exp. Pharmacol. Physiol., 26, 168-171.
12. KOVACS, E.J. & DIPIETRO, L.A. (1994). Fibrogenic cytokines and connective tissue production. FASEB J., 8, 854-861.
13. LOVE, M.P. & MCMURRAY, J.J.V. (1996). Endothelin in chronic heart failure: current position and future prospects. Cardiovas. Res., 31, 665-674.
14. MACLEAN, M.R. (1999). Endothelin-1 and serotonin: mediators of primary and secondary pulmonary hypertension? J. Lab. Clin. Med., 134, 105-114.
15. MARINI, M., CARPI, S., BELLINI, A., PATALANO, F. & MATTOLI, S. (1996). Endothelin-1 induces increased fibronectin expression in human bronchial epithelial cells. Biochem. Biophys. Res. Commun., 220, 896-899.
16. MOREAU, P., D'USCIO, L.V., SHAW, S., TAKASE, H., BARTON, M. & LUSCHER, T.F. (1997). Angiotensin II increases tissue endothelin and induces vascular hypertrophy: reversal by ET(A)-receptor antagonist. Circulation, 96, 1593-1597.
17. A-receptor antagonist inhibits neointima formation induced by endothelial injury. Pharm. Pharmacol. Lett., 2, 90-92.
18. 1,3,11,15)ET-1. Biochim. Biophys. Res. Commun., 182, 144-150.
19. NAKAO, A., FUJII, M., MATSUMURA, R., KUMANO, K, SAITO, Y., MIYAZONO, K. & IWAMOTO, I. (1999). Transient gene transfer and expression of Smad7 prevents bleomycin-induced lung fibrosis in mice. J. Clin. Invest., 104, 5-11.
20. NGUYEN, Q.T., CERNACEK, P., CALDERONE, A., STEWART, D.J., PICARD, P., SIROIS, P., WHITE, M. & ROULEAU, J.L. (1998). Endothelin A receptor blockade causes adverse left ventricular remodeling but improves pulmonary artery pressure after infarction in the rat. Circulation, 98, 2323-2330.
21. PARK, S.H., SALEH, D., GIAID, A. & MICHEL, R.P. (1997). Increased endothelin-1 in bleomycin-induced pulmonary fibrosis and the effect of an endothelin receptor antagonist. Am. J. Respir. Crit. Care. Med., 156, 600-608.
22. PICARD, P., SMITH, P.J.W., MONGE, J.C., ROULEAU, J.L., NGUYEN, Q.T., CALDERONE, A. & STEWART, D.J. (1998). Coordinated upregulation of the cardiac endothelin system in a rat model of heart failure. J. Cardiovas. Res., 31(Suppl. 1), S294-S297.
23. PRIÉ, S., LEUNG, T.K., CERNACEK, P., RYAN, J.W. & DUPUIS, J. (1997). The orally active ET(A) receptor antagonist (+)-(S)-2-(4,6-dimethoxy-pyrimidin-2-yloxy)-3-methoxy-3,3-diphe nylpropionic acid (LU135252) prevents the development of pulmonary hypertension and endothelial metabolic dysfunction in monocrotaline-treated rats. J. Pharmacol. Exp. Ther., 282, 1312-1318.
24. RIZVI, M.A. & MYERS, P.R. (1997). Nitric oxide modulates basal and endothelin-induced coronary artery vascular smooth muscle cell proliferation and collagen levels. J. Mol. Cell. Cardiol., 29, 1779-1789.
25. SAKAI, S., MIYAUCHI, T., KOBAYASHI, M., YAMAGUCHI, I., GOTO, K. & SUGISHITA, Y. (1996a). Remarkable improvement in long-term mortality and prevention of unfavourable ventricular remodelling by inhibition of the upregulated myocardial endothelin pathway in rats. Nature, 384, 353-355.
26. SAKAI, S., MIYAUCHI, T., SAKURAI, T., YAMAGUCHI, I., KOBAYASHI, M., GOTO, K. & SUGISHITA, Y. (1996b). Pulmonary hypertension caused by congestive heart failure is ameliorated by long-term application of an endothelin receptor antagonist: Increased expression of endothelin-1 messenger ribonucleic acid and endothelin-1-like immunoreactivity in the lung in congestive heart failure in rats. J. Am. Coll. Cardiol., 28, 1580-1588.
27. ras. Am. J. Physiol., 272, C2019-C2030.
28. SCHIFFRIN, E.L. (1998). Endothelin and endothelin antagonists in hypertension. J. Hypertens., 16, 1891-1895.
29. SIME, P.J., XING, Z., GRAHAM, F.L., CSAKY, K.G. & GAULDIE, J. (1997). Adenovector-mediated gene transfer of active transforming growth factor-beta1 induces prolonged severe fibrosis in rat lung. J. Clin. Invest., 100, 768-776.
30. SOMA, S., TAKAHASHI, H., MURAMATSU, M., OKA, M. & FUKUCHI, Y. (1999). Localization and distribution of endothelin receptor subtypes in pulmonary vasculature of normal and hypoxia-exposed rats. Am. J. Respir. Cell. Mol. Biol., 20, 620-630.
31. STEWART, D.J. (1993). Endothelin in cardiopulmonary disease: factor paracrine vs neurohumoral. Eur. Heart. J., 14 (Suppl 1), 48-54.
32. YANG, Z., KRASNICI, N. & LUSCHER, T.F. (1999). Endothelin-1 potentiates human smooth muscle cell growth to PDGF: effects of ETA and ETB receptor blockade. Circulation, 100, 5-8.
33. ZHANG, K. & PHAN, S.H. (1996). Cytokines and pulmonary fibrosis. Biol. Signals, 5, 232-239.